Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS)

References

• Bachleitner-Hofmann T, Sun MY, Chen CT, et al. (2011). Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET inhibition. Clin Cancer Res 17:122–33
   PubMed Web of Science ®Google Scholar
• Barta TE, Veal JM, Rice JW, et al. (2008). Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. Bioorg Med Chem Lett 18:3517–21
   PubMed Web of Science ®Google Scholar
• Bateman KP, Castro-Perez J, Wrona M, et al. (2007). MSE with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Commun Mass Spectrom 21:1485–96
   PubMed Web of Science ®Google Scholar
• Castro-Perez JM. (2007). Current and future trends in the application of HPLC-MS to metabolite-identification studies. Drug Discov Today 12:249–56
   PubMed Web of Science ®Google Scholar
• Chandarlapaty S, Sawai A, Ye Q, et al. (2008). SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 14:240–8
   PubMed Web of Science ®Google Scholar
• Chinn DC, Holland WS, Yoon JM, et al. (2012). Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines. Pediatr Blood Cancer 58:885–90
   PubMed Web of Science ®Google Scholar
• Csermely P, Schnaider T, Soti C, et al. (1998). The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 79:129–68
   PubMed Web of Science ®Google Scholar
• Deng P, You T, Chen X, et al. (2011). Identification of amiodarone metabolites in human bile by ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry. Drug Metab Dispos 39:1058–69
   PubMed Web of Science ®Google Scholar
• Deng P, Zhong D, Yu K, et al. (2013). Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans. Antimicrob Agents Chemother 57:1743–55
   PubMed Web of Science ®Google Scholar
• Ding J, Chen X, Gao Z, et al. (2013). Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans. Drug Metab Dispos 41:1195–210
   PubMed Web of Science ®Google Scholar
• Dong D, Wu B, Chow D, Hu M. (2012). Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Drug Metab Rev 44:192–208
   PubMed Web of Science ®Google Scholar
• Gong A, Chen X, Deng P, Zhong D. (2010). Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients. Drug Metab Dispos 38:1328–40
   PubMed Web of Science ®Google Scholar
• Hallifax D, Houston JB. (2006). Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 34:724–46
   PubMed Web of Science ®Google Scholar
• Huang KH, Veal JM, Fadden RP, et al. (2009). Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem 52:4288–305
   PubMed Web of Science ®Google Scholar
• Liu H, Ma Z, Wu B. (2013). Structure–activity relationships and in silico models of P-glycoprotein (ABCB1) inhibitors. Xenobiotica 43:1018--26
   Google Scholar
• Liu KS, Ding WC, Wang SX, et al. (2012a). The heat shock protein 90 inhibitor SNX-2112 inhibits B16 melanoma cell growth in vitro and in vivo. Oncol Rep 27:1904–10
   PubMed Web of Science ®Google Scholar
• Liu KS, Liu H, Qi JH, et al. (2012b). SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells. Cancer Lett 318:180–8
   PubMed Web of Science ®Google Scholar
• Mortishire-Smith RJ, Castro-Perez JM, Yu K, et al. (2009). Generic dealkylation: a tool for increasing the hit-rate of metabolite rationalization, and automatic customization of mass defect filters. Rapid Commun Mass Spectrom 23:939–48
   PubMed Web of Science ®Google Scholar
• Nassar AE, Talaat RE. (2004). Strategies for dealing with metabolite elucidation in drug discovery and development. Drug Discov Today 9:317–27
   PubMed Web of Science ®Google Scholar
• Neckers L, Neckers K. (2005). Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics: an update. Expert Opin Emerg Drugs 10:137–49
   PubMedGoogle Scholar
• Okawa Y, Hideshima T, Steed P, et al. (2009). SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 113:846–55
   PubMed Web of Science ®Google Scholar
• Palmeira A, Sousa E, Vasconcelos MH, et al. (2012a). Structure and ligand-based design of P-glycoprotein inhibitors: a historical perspective. Curr Pharm Des 18:4197–214
   PubMed Web of Science ®Google Scholar
• Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. (2012b). Three decades of P-gp inhibitors: skimming through several generations andscaffolds. Curr Med Chem 19:1946–2025
   PubMed Web of Science ®Google Scholar
• Rajan A, Kelly RJ, Trepel JB, et al. (2011). A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 17:6831–9
   PubMed Web of Science ®Google Scholar
• Ramanathan R, Jemal M, Ramagiri S, et al. (2011). It is time for a paradigm shift in drug discovery bioanalysis: from SRM to HRMS. J Mass Spectrom 46:595–601
   PubMed Web of Science ®Google Scholar
• Ranasinghe A, Ramanathan R, Jemal M, et al. (2012). Integrated quantitative and qualitative workflow for in vivo bioanalytical support in drug discovery using hybrid Q-TOF-MS. Bioanalysis 4:511–28
   PubMed Web of Science ®Google Scholar
• Walsh AA, Szklarz GD, Scott EE. (2013). Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism. J Biol Chem 288:12932–43
   PubMed Web of Science ®Google Scholar
• Wang R, Shao F, Liu Z, et al. (2013). The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent pathways. Chem Biol Interact 205:1–10
   PubMed Web of Science ®Google Scholar
• Wang SX, Ju HQ, Liu KS, et al. (2011). SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells. Biosci Biotechnol Biochem 75:1540–5
   PubMed Web of Science ®Google Scholar
• Wrona M, Mauriala T, Bateman KP, et al. (2005). ‘All-in-one’ analysis for metabolite identification using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry with collision energy switching. Rapid Commun Mass Spectrom 19:2597–602
   PubMed Web of Science ®Google Scholar
• Xie C, Zhong D, Yu K, Chen X. (2012). Recent advances in metabolite identification and quantitative bioanalysis by LC-Q-TOF MS. Bioanalysis 4:937–59
   PubMed Web of Science ®Google Scholar
• Xie C, Zhou J, Guo Z, et al. (2013). Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol 168:1687–706
   PubMed Web of Science ®Google Scholar
• Ye L, Wang T, Yang C, et al. (2011). Microsomal cytochrome P450-mediated metabolism of hypaconitine, an active and highly toxic constituent derived from Aconitum species. Toxicol Lett 204:81–91
   PubMed Web of Science ®Google Scholar
• Zhai QQ, Gong GQ, Liu Z, et al. (2011). Preclinical pharmacokinetic analysis of SNX-2112, a novel Hsp90 inhibitor, in rats. Biomed Pharmacother 65:132–6
   PubMed Web of Science ®Google Scholar
• Zhang NR, Yu S, Tiller P, et al. (2009). Quantitation of small molecules using high-resolution accurate mass spectrometers – a different approach for analysis of biological samples. Rapid Commun Mass Spectrom 23:1085–94
   PubMed Web of Science ®Google Scholar
• Zhou J, Tracy TS, Remmel RP. (2010). Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites. Drug Metab Dispos 38:431–40
   PubMed Web of Science ®Google Scholar